Italy’s antitrust regulator has initiated an investigation into several pharmaceutical giants, including Novartis AG (NYSE:NVS) and Roche Holdings AG (OTC:RHHBY)-controlled Genentech, for allegedly restricting competition in the sale of an eye drug.
The probe focuses on potential delays in the Italian market launch of Byooviz, a ranibizumab-based drug developed by Samsung Bioepis, due to coordinated strategies by these companies and their subsidiaries in Italy, the Netherlands, and the U.K.
Reuters noted that the Italian watchdog, supported by the finance police, carried out searches in Italy ...